relapsed/refractory

Hematology-Oncology Wellness & Lifestyle

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

By MedXY 10/14/2025

The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.

$Five-Year Outcomes of FCARH143: A Fully Human BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma$

Clinical Updates Hematology-Oncology Specialties

Five-Year Outcomes of FCARH143: A Fully Human BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

By MedXY 08/29/2025

FCARH143, a fully human BCMA-directed CAR-T cell therapy, shows remarkable long-term efficacy and manageable safety profile in heavily pretreated relapsed/refractory multiple myeloma patients over 5 years.

$Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study$

Hematology-Oncology Specialties

Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study

By MedXY 08/29/2025

This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.